British Business Bank Backs Apposite Capital’s New Healthtech Fund with Record £100m Commitment
The British Business Bank has made its largest single fund commitment ever, a £100 million cornerstone investment into Apposite Capital’s newly launched Apposite Healthcare Growth I fund. This British Business Bank healthtech fund marks the institution’s first partnership with Apposite Capital, a specialist healthcare and life sciences investor, and signals a serious escalation in the UK’s push to keep its most promising medical companies from fleeing abroad.
The fund is designed to target innovative companies operating across medical products, diagnostics, life sciences tools, digital health, and pharmaceutical outsourcing services, precisely the segments where the UK has world-class talent but has historically struggled to provide adequate growth capital.
The timing isn’t accidental. For years, UK life sciences companies at a critical growth inflection point have found themselves caught in an awkward middle ground, too large for early-stage venture money, and too small or unproven for traditional private equity. The result has been a wave of premature exits or businesses relocating to markets with deeper capital pools. This British Business Bank healthtech fund is a direct attempt to plug that gap before it widens further.
As the largest investor in UK venture and venture growth capital funds, the Bank frequently acts as a cornerstone backer to help funds hit their first close, giving them the credibility and scale to execute properly. This commitment fits that pattern, but at an unprecedented size.
Christine Hockley, managing director and co-head of funds at the British Business Bank, made the intent clear: the Bank is actively targeting over 60 per cent of its venture and growth investment flow toward scale-up businesses, and plans to support the launch of 10 new growth-stage funds over the next five years by writing bigger cheques to high-conviction fund managers.
Mark Andrews, investment director of funds and life sciences at the Bank, pointed directly to the structural problem in the sector. Many promising life sciences companies, he noted, cannot fulfil their potential within the UK and are pushed toward premature or suboptimal exits simply because the later-stage funding infrastructure does not exist to carry them through.
Sam Gray, managing partner at Apposite Capital, framed the fund as a bridge between world-class British scientific research and global commercial scale, enabling high-potential companies to accelerate their growth, bring transformative technologies to market, and improve patient outcomes while simultaneously supporting economic growth.
The investment also carries clear government backing. Peter Kyle, Secretary of State for Science, Innovation and Technology, described the move as a direct delivery on the government’s promise to back the UK’s most ambitious healthtech firms, giving them the financial firepower to develop cutting-edge medical products, advance diagnostics, and improve healthcare across the country.
For a sector that has long complained of being rich in ideas but starved of capital at the right stage, this British Business Bank healthtech fund represents more than a single investment, it is a statement of intent about where the UK wants to compete.
